CD8A and neoplasm: In addition, Zou et al39 developed a DNA methylation signature signal based on CD8+ tumor-infiltrating lymphocytes that can be used to evaluate the immune response of CD8+ tumor-infiltrating lymphocytes in CRC, and the DNA methylation signal of CD8+ tumor-infiltrating lymphocytes may become a potential biomarker for CRC.